A Global Randomized Trial Evaluating the FARAFLEX™ Mapping and Pulsed Field Ablation System With Electrographic Flow Mapping in Patients Undergoing Repeat Ablation for Atrial Fibrillation

A trial with no phase registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 650 participants.

Also called NCT07820930

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 650 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07820930
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07820930. Randomized; no masking; primary purpose treatment. Start 2026-11 (anticipated); primary completion 2029-07 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Global Randomized Trial Evaluating the FARAFLEX™ Mapping and Pulsed Field Ablation System With Electrographic Flow Mapping in Patients Undergoing Repeat Ablation for Atrial Fibrillation
Acronym
ReDEFINE-AF
Condition
Atrial Fibrillation (AF)
Condition
Persistent Atrial Fibrillation (PersAF)
Condition
Paroxysmal Atrial Fibrillation (PAF)
Intervention (Device)
FARAFLEX Mapping and Pulsed Field Ablation System
Lead sponsor
Boston Scientific Corporation (class: industry)

Record details

Record id
cardio:ct-nct07820930
Content hash
b8ee4c68589de7d3f9403c3c8f0ce02cb5360085a00578853b15cdd4bbe94f33